Immunovant (IMVT)
(Delayed Data from NSDQ)
$27.17 USD
-0.58 (-2.09%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $27.13 -0.04 (-0.15%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth D Momentum D VGM
Income Statements
Fiscal Year end for Immunovant, Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | NA | 0 | 0 | 0 | 0 |
Cost Of Goods | NA | 0 | 0 | 0 | 0 |
Gross Profit | NA | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 218 | 156 | 108 | 66 |
Income After Depreciation & Amortization | 0 | -218 | -156 | -108 | -66 |
Non-Operating Income | NA | 7 | -1 | 0 | 0 |
Interest Expense | NA | 0 | 0 | 0 | 1 |
Pretax Income | NA | -211 | -157 | -108 | -66 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -211 | -157 | -107 | -66 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -211 | -157 | -107 | -66 |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -218 | -156 | -108 | -66 |
Depreciation & Amortization (Cash Flow) | NA | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | 0 | -218 | -156 | -108 | -66 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | NA | 123.08 | 109.68 | 87.76 | 43.20 |
Diluted EPS Before Non-Recurring Items | NA | -1.71 | -1.43 | -1.22 | -1.54 |
Diluted Net EPS (GAAP) | NA | -1.71 | -1.43 | -1.22 | -1.54 |
Fiscal Year end for Immunovant, Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 61.56 | 61.80 | 78.48 | 64.26 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -61.56 | -61.80 | -78.48 | -64.26 |
Non-Operating Income | NA | 10.03 | 3.59 | 4.53 | 3.84 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -51.53 | -58.21 | -73.95 | -60.42 |
Income Taxes | NA | -0.11 | 0.45 | -0.01 | -0.99 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -51.42 | -58.66 | -73.94 | -59.43 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -51.42 | -58.66 | -73.94 | -59.43 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 144.52 | 131.16 | 130.50 | 129.63 |
Diluted EPS Before Non-Recurring Items | NA | -0.36 | -0.45 | -0.47 | -0.46 |
Diluted Net EPS (GAAP) | NA | -0.36 | -0.45 | -0.57 | -0.46 |